Staar Surgical Co (STAA) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst Challenges

GuruFocus.com11-02 21:00

Net Sales: $88.6 million, a 10% increase from the prior year quarter. ICL Sales Growth: $8 million increase, representing a 10% growth. Gross Profit: $68.5 million, 77.3% of net sales, down from 79.2%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2480482925?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/._.1DMeGK8vhiD48xnP5rg--~B/aD0yMDg7dz0yMzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/488d297aefc0d65f96f7bcb442904e85","is_english":true,"pubTime":"2024-11-02 21:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2480482925","market":"us","top_or_hot":-1,"title":"Staar Surgical Co (STAA) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst Challenges","media":"GuruFocus.com","content":"<div>\n<p>Net Sales: $88.6 million, a 10% increase from the prior year quarter.\nICL Sales Growth: $8 million increase, representing a 10% growth.\nGross Profit: $68.5 million, 77.3% of net sales, down from 79.2%...</p>\n\n<a href=\"https://finance.yahoo.com/news/staar-surgical-co-staa-q3-130023315.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Staar Surgical Co (STAA) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst Challenges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStaar Surgical Co (STAA) Q3 2024 Earnings Call Highlights: Strong Sales Growth Amidst Challenges\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-02 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/staar-surgical-co-staa-q3-130023315.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Net Sales: $88.6 million, a 10% increase from the prior year quarter.\nICL Sales Growth: $8 million increase, representing a 10% growth.\nGross Profit: $68.5 million, 77.3% of net sales, down from 79.2%...</p>\n\n<a href=\"https://finance.yahoo.com/news/staar-surgical-co-staa-q3-130023315.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STAA","symbol_name":"STAAR Surgical Company","start_time":0,"source_url":"https://finance.yahoo.com/news/staar-surgical-co-staa-q3-130023315.html","article_id":"2480482925","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/._.1DMeGK8vhiD48xnP5rg--~B/aD0yMDg7dz0yMzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/488d297aefc0d65f96f7bcb442904e85"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2480482925","pubTimestamp":1730552423,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Net Sales: $88.6 million, a 10% increase from the prior year quarter.ICL Sales Growth: $8 million increase, representing a 10% growth.Gross Profit: $68.5 million, 77.3% of net sales, down from 79.2% in the prior year.Operating Expenses: Increased 10% to $62.8 million from $57.3 million in Q3 2023.GAAP Net Income: $10 million or 20 per diluted share, up from $4.8 million or 10 per diluted share in the prior year quarter.Adjusted EBITDA: $16.2 million or 33 per diluted share.Cash and Investments: $236 million, up from $232.4 million in December 2023.CapEx Expectation: Approximately $30 million for fiscal 2024.Regional Sales Growth: Americas 14%, EMEA 12%, APAC 9%.GuruFocus has detected 4 Warning Signs with STAA.Staar Surgical Co  achieved net sales of $88.6 million, reflecting double-digit sales growth despite a challenging macroeconomic environment.Staar Surgical Co  maintains a strong balance sheet with $236 million in cash, cash equivalents, and investments, providing flexibility for ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"STAA":"STAAR Surgical Company"},"translate_title":"Staar Surgical Co(STAA)2024年第三季度收益看涨期权亮点：挑战中销售强劲增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STAA":1},"content_text":"Net Sales: $88.6 million, a 10% increase from the prior year quarter.\nICL Sales Growth: $8 million increase, representing a 10% growth.\nGross Profit: $68.5 million, 77.3% of net sales, down from 79.2% in the prior year.\nOperating Expenses: Increased 10% to $62.8 million from $57.3 million in Q3 2023.\nGAAP Net Income: $10 million or 20 per diluted share, up from $4.8 million or 10 per diluted share in the prior year quarter.\nAdjusted EBITDA: $16.2 million or 33 per diluted share.\nCash and Investments: $236 million, up from $232.4 million in December 2023.\nCapEx Expectation: Approximately $30 million for fiscal 2024.\nRegional Sales Growth: Americas 14%, EMEA 12%, APAC 9%.\nChina Sales Growth: 7% increase.\nJapan Sales Growth: 15% increase.\nSouth Korea Sales Growth: 11% increase.\n\n\nWarning! GuruFocus has detected 4 Warning Signs with STAA.\n\nRelease Date: October 30, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nStaar Surgical Co (NASDAQ:STAA) achieved net sales of $88.6 million, reflecting double-digit sales growth despite a challenging macroeconomic environment.\nThe company celebrated the grand opening of the new EVO ICL Experience Center, which is designed to enhance training and education for surgeons and healthcare staff.\nStaar Surgical Co (NASDAQ:STAA) reported strong regional performance, with 14% sales growth in the Americas and 12% in EMEA, driven by the Middle East and European distributor markets.\nThe company continues to gain market share in key regions, including a 16% sales growth in the US and 15% in Japan.\nStaar Surgical Co (NASDAQ:STAA) maintains a strong balance sheet with $236 million in cash, cash equivalents, and investments, providing flexibility for capital allocation decisions.\n\n Negative Points \n\nThe macroeconomic environment in China softened, impacting sales momentum in the second half of the quarter.\nGross profit margin decreased to 77.3% from 79.2% due to reduced unit production and less absorption of fixed overhead.\nOperating expenses increased by 10% year-over-year, driven by higher facilities costs and compensation-related expenses.\nThe US refractive market was more challenging than anticipated, with a 18% year-over-year decline.\nThe company faces potential competitive pressure in China from new entrants in the implantable lens category.\n\n Q & A Highlights \nQ: Can you provide insights on the expected growth for 2025, considering the current macroeconomic dynamics? A: Thomas Frinzi, Chairman of the Board, President, and CEO, stated that it is premature to comment on the 2025 outlook. However, he emphasized the company's history of outpacing the market and expressed confidence in their ability to continue being a growth-oriented company with a strong track record.\nQ: What are the current trends in China, and how are they affecting your guidance for the fourth quarter? A: Thomas Frinzi noted that the high season in China saw a slowdown in sales following the Q2 earnings call in August. Despite the challenges, STAAR Surgical continued to gain market share. The company believes these headwinds are transitory and is encouraged by the Chinese government's stimulus and economic packages.\nQ: How is the US market performing, especially in comparison to laser vision correction trends? A: Thomas Frinzi highlighted that despite the US laser vision correction market being down 18% in the quarter, STAAR Surgical grew 16%. The company is pleased with this performance and continues to take market share, particularly through their Highway 93 initiative.\nQ: Can you elaborate on the strong performance in the EMEA region and the factors contributing to it? A: Thomas Frinzi attributed the strong performance in the EMEA region to robust sales in the Middle East and European distributor markets. He also mentioned successful initiatives in the UK, Spain, and Germany, where the company is direct, and highlighted the AON 50 strategy as a key growth driver.\nQ: What is the competitive landscape in China, and how is STAAR Surgical positioned against competitors? A: Thomas Frinzi acknowledged the presence of competition, particularly from iBright, which is expected to enter the market in 2025. He emphasized STAAR Surgical's advantages, such as their Collamer material and toric version, and expressed confidence in maintaining a premium position due to superior outcomes.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2480482925"}